The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of Japan: Marked Hyperalphalipoproteinemia Caused by CETP Gene Mutation Is Not Associated With Longevity
Abstract
Abstract Low levels of HDL cholesterol have been clearly demonstrated to be associated with an increased incidence of coronary heart disease, strongly suggesting that HDL particles have an antiatherogenic function. However, little information has been available concerning the atherogenicity of a marked hyperalphalipoproteinemia (HALP). There is no agreement about whether plasma cholesteryl ester transfer protein (CETP) deficiency is associated with an antiatherogenic state or not, although this disorder was reported to be one of the major causes of marked HALP. In the current study, we have found a unique area (Omagari City, Akita Prefecture, Japan) where CETP deficiency caused by a G-to-A mutation at the 5′ splice donor site of intron 14 in the CETP gene is extremely frequent. In Omagari City, the mutation was detected more than 20 times more frequently and the prevalence of a marked HALP with plasma HDL cholesterol ≥2.58 mmol/L (100 mg/dL) was 5 to 10 times higher than in other areas of Japan. This discovery has made it possible to perform a large population-based study concerning the atherogenicity of a marked elevation of HDL cholesterol in a genetically more homogeneous population. There was a statistically significant U-shaped relationship between HDL cholesterol levels and the incidence of ischemic changes in electrocardiograms. In cases of HDL cholesterol <1.81 mmol/L (70 mg/dL), the incidence increased in proportion to the levels of HDL cholesterol. The frequency of the CETP gene mutation was higher in patients with coronary heart disease than in healthy control subjects. In subjects aged >80 years, the prevalence of both marked HALP and the intron 14 splicing defect was significantly lower than in the younger generation. The current study indicated for the first time that a marked HALP caused by CETP gene mutation may not represent a longevity syndrome, suggesting the importance of reevaluation of the clinical significance and pathophysiology of a marked HALP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The recent CREDO-Kyoto study has also reported that a family history of CAD contributes to the occurrence of major cardiovascular events at a young age174).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [174]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,807
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Miller, N. E., Thelle, D. S., Førde, O. H., & Mjøs, O. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92274-7 · Cited by 1,206
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 862
Brown, M. L., Inazu, A., Hesler, C. B., Agellon, L. B., Mann, C., Whitlock, M. E., Marcel, Y. L., Milne, R. W., Koizumi, J., Mabuchi, H., et al. (1989) · Nature · doi:10.1038/342448a0 · Cited by 470
Hobbs, H. H., Brown, M. S., Russell, D. W., Davignon, J., & Goldstein, J. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709173171204 · Cited by 301
Hayek, T., Masucci-Magoulas, L., Jiang, X. L., Walsh, A., Rubin, E. M., Breslow, J. L., & Tall, A. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118255 · Cited by 265
Reichl, D., & Miller, N. E. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.6.785 · Cited by 238
Research works printed but not linked: 9
- 10.1161/atv91.11.1.1988006 · DOI
- 10.1161/atvb.15.11.1849 · DOI
- 1978, Clin Chem, 24, 24
- Hishinuma J. Municipal Life Tables 1990 . Health and Welfare Statistics Association; 1993:44-45.
- 1993, Hum Genet, 91, 13
- 10.1016/0002-9343(77)90874-9 · DOI · Paper page
- 10.1161/circ.88.6.8252679 · DOI
- 1995, Ann NY Acad Sci, 748, 606
- 1992, Arch Pathol Lab Med, 116, 831
Cited by
Sorted by citations
Items 201–277 of 277
Zende, P. D. (2014) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2014/7818.4441 · Cited by 5
The conscientious judgement of a DSMB – statistical stopping rules re-examined
Hedenmalm, K., Melander, H., & Alván, G. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0403-4 · Cited by 5
Nissen, S. E. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.208 · Cited by 5
Toth, P. P. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_9 · Cited by 5
High-Density Lipoprotein Metabolism
Brewer, H. B. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_5 · Cited by 5
Krikken, J. A., Dallinga‐Thie, G. M., Navis, G., & Dullaart, R. P. F. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1321 · Cited by 5
Biologic therapies for dyslipidemia
Davidson, M. H. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0118-2 · Cited by 5
CETP Inhibitors: Back With a New Target
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2026) · Circulation Research · doi:10.1161/circresaha.125.327271 · Cited by 4
Yokoyama, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.807289 · Cited by 4
Newer pharmaceutical agents to treat lipid disorders
Davidson, M. H. (2003) · Current Cardiology Reports · doi:10.1007/s11886-003-0108-y · Cited by 4
Treating low HDL—From bench to bedside
Ng, D. S. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.04.005 · Cited by 4
YOSHIDA, A., Kodama, M., Nomura, H., KOBAYASHI, N., Sumida, K., & Naito, M. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.357 · Cited by 4
Mabuchi, H., & Inazu, A. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.487 · Cited by 4
Intrinsic enzymes of high-density lipoprotein
Le, N., & Walter, M. F. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.01.005 · Cited by 4
Matsuzawa, Y., Kita, T., Shepherd, J., Gotto, A. M., Nakamura, H., Sacks, F. M., Oikawa, S., & Sasaki, J. (2007) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2007.02.004 · Cited by 4
Self-citationHepatic aberrant glycosylation byN-acetylglucosaminyltransferase V accelerates HDL assembly
Kamada, Y., Kida, S., Hirano, K., Yamaguchi, S., Suzuki, A., Hashimoto, C., Kimura, A., Sato, M., Fujii, H., Sobajima, T., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00231.2016 · Cited by 4
Self-citationSirtori, C. R., Calabresi, L., Baldassarre, D., Franceschini, G., Cefalu, A. B., & Averna, M. R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.024 · Cited by 4
Is Cholesteryl Ester Transfer Protein (CETP) Deficiency Atherogenic in Familial Hypercholesterolemia
Saitō, Y. (1998) · Internal Medicine · doi:10.2169/internalmedicine.37.495 · Cited by 4
Genetics and molecular biology
García-Otín, A. L., & Zakin, M. M. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00015 · Cited by 3
Giraldo, A. M., Loango, N., Castaño, H., & Landázuri, P. (2012) · Revista Colombiana de Cardiología · doi:10.1016/s0120-5633(12)70127-4 · Cited by 3
Genetics and molecular biology
Ochoa, A., & Zakin, M. M. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200002000-00013 · Cited by 3
Effects of pitavastatin on HDL metabolism
Kishida, K., Funahashi, T., & Shimomura, I. (2013) · Clinical Lipidology · doi:10.2217/clp.12.87 · Cited by 3
Masuda, D., & Yamashita, S. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed049 · Cited by 3
Self-citationHigh-Density Lipoprotein Metabolism
Brewer, H. B. (2009) · Clinical Lipidology · doi:10.1016/b978-141605469-6.50008-1 · Cited by 3
Cholesterol transport in blood, lipoproteins, and cholesterol metabolism
Auley, M. T. M., & Morgan, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00025-0 · Cited by 3
High-Density Lipoprotein Metabolism
Brewer, H. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00004-9 · Cited by 3
Les dyslipidémies héréditaires
Couvert, P., Giral, P., Bonnefont‐Rousselot, D., & Carrié, A. (2010) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(10)70646-8 · Cited by 2
Familial Hypercholesterolemia with Cholesteryl Ester Transfer Protein Deficiency.
Kamigaki, M., Tsuji, M., ISHII, J., Hata, A., Chiba, H., Akita, H., Hirayama, T., & Emi, M. (1998) · Internal Medicine · doi:10.2169/internalmedicine.37.523 · Cited by 2
Iwasaki, Y., Takahashi, M., Nozu, K., Matsumoto, S., & Koshiyama, H. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5515 · Cited by 2
Cholesteryl Ester Transfer Protein Inhibitors
Inazu, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-407867-3.00008-1 · Cited by 2
Pediatric dyslipidemias: lipoprotein metabolism disorders in children
Ballout, R. A., & Remaley, A. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00002-0 · Cited by 3
Genetic Disorders of HDL Metabolism
Lilley, J. S., Linton, M. F., & Fazio, S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_12 · Cited by 2
Low HDL and High HDL Syndromes
Yamashita, S., & Matsuzawa, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.04000-9 · Cited by 2
Self-citationFutatsugi, A., Tozuka, M., Horiuchi, Y., Ohkawa, R., & Kosho, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-74699-5 · Cited by 1
Kumada, M., Munkhtulga, L., Utsumi, N., Omi, T., Gotoh, T., Kamesaki, T., Okuda, H., Kajii, E., & Iwamoto, S. (2008) · Public Health Genomics · doi:10.1159/000113877 · Cited by 1
Génétique et HDL : anomalies rares héréditaires
Couvert, P., & Carrié, A. (2011) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(11)70783-2 · Cited by 1
Yachida, J., Fujihara, K., Yamada, M. H., Kobayashi, A., KHIN, L. M., TAKIZAWA, H., Yamamoto, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15956 · Cited by 3
Gender Difference in High-density Lipoprotein Cholesterol in Japanese
Takahashi, E., Moriyama, K., & Yamada, C. (2012) · Ningen dock : official journal of the Japanese Society of Human Dry Dock · doi:10.11320/ningendock.27.108 · Cited by 1
Le vieillissement réussi : enseignement des modèles japonais et suédois
Kim-Esnault, Y.-U. (2008) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2008.01.008 · Cited by 1
Santos‐Gallego, C. G., & Badimón, J. J. (2012) · Revista Colombiana de Cardiología · doi:10.1016/s0120-5633(12)70128-6 · Cited by 1
Hirano, K., Yamashita, S., Sakai, N., & Matsuzawa, Y. (2004) · Elsevier eBooks · doi:10.1016/b0-12-475570-4/00587-4 · Cited by 1
Self-citationClearfield, M. B. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0002-6 · Cited by 1
High-Density Lipoprotein Cholesterol in Coronary Heart Disease Risk Assessment
Miller, M. J. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50014-7 · Cited by 1
Impairment of Reverse Cholesterol Transport System and Atherosclerosis
Yamashita, S., Maruyama, T., Hirano, K., Sakai, N., Nakajima, N., & Matsuzawa, Y. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_25 · Cited by 1
Self-citationOtsuka, T. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed208 · Cited by 1
Genetic risks for cardiovascular diseases
Zafarmand, M. H. (2008) · Utrecht University Repository (Utrecht University)
Improving cardiovascular disease prevention : from risk assessment to novel therapy
van der Steeg, W. A. (2009) · UvA-DARE (University of Amsterdam)
Cholesteryl ester transfer protein deficiency is correlated with thyroid disease.
Feng, Y.-P., Kondo, A., Maekawa, M., & Kanno, T. (2001) · SEIBUTSU BUTSURI KAGAKU · doi:10.2198/sbk.45.65
A Korean Family with Cholesterol Ester Transfer Protein Deficiency
Youn, S. Y., Shin, I. S., Hong, Y. H., & Lee, D. H. (2012) · Journal of genetic medicine · doi:10.5734/jgm.2012.9.1.38
The mechanism of high-density lipoprotein cholesterol elevation in patients treated with simvastatin
Tsuji, M., Ide, H., Yabunaka, N., Otsuka, Y., Tsuchihashi, K., & Gasa, S. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85103-5
Aging and High-Density Lipoprotein Metabolism
Arai, Y., & Hirose, N. (2006) · Aging Health · doi:10.2217/1745509x.2.4.611
CETP Pharmacological Manipulation Transforming Human into Mouse: Is this Still a Viable Hypothesis?
Morales-Villegas, E., Moreno-Virgen, G., & Barter, P. J. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212803521057
Anninos, H., & Manolis, A. S. (2012) · Hospital chronicles/Hospital Chronicles
The puzzle of high-density lipoprotein in cardiovascular prevention
El-Harchaoui, A. (2009) · UvA-DARE (University of Amsterdam)
III. Abnormalities in Lipid Metabolism in Chronic Kidney Disease
Shoji, T. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.923
Formes rares de dyslipidémies génétiques
Luc, G. (2010) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(10)51264-2
Aronow, W. S. (2013) · doi:10.2217/fmeb2013.13.81
Gandotra, P., & Miller, M. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00013-5
Molecular Mechanisms of Hyperalphalipoproteinemia
Yamashita, S., Masuda, D., Ohama, T., & Koseki, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00001-x
Self-citationPatil, R. V., Cheng, C., Cheung, C. M. G., & Wong, T. Y. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_37
Wehling, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800687-0.00034-7
Yamashita, S., Maruyama, T., Hirano, K., Sakai, N., Nakajima, N., & Matsuzawa, Y. (2000)
Self-citationThe highs and lows of high-density lipoprotein
Soffer, D. E., & Schoen, M. A. (2013) · doi:10.2217/fmeb2013.13.77
[First-line chemotherapy for unresectable and metastatic colorectal cancer].
Satoh, T. (2014) · PubMed
高比重リポ蛋白(HDL)の新たな機能評価法の実用化と心血管病リスクの層別化
隆嗣, 杜., & Ishida, T. (2017) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.25.2_150
Giraldo, A. M., Castaño, H., & Landázuri, P. (2012) · Revista Colombiana de Cardiología
Cegla, J., & Scott, J. (2020) · doi:10.1093/med/9780198746690.003.0232
Wehling, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00027-1
Berkowitz, L., Flaherty, S., Kitayama, S., Karasawa, M., Kawakami, N., Rigotti, A., & Coe, C. L. (2024) · Antioxidants · doi:10.3390/antiox13121434 · Cited by 1
Yamashita, S., & Masuda, D. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.16
Self-citationLow HDL and high HDL syndromes
Yamashita, S., & Matsuzawa, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00305-8
Self-citationAssociations of plasma HDL subclasses with incident dementia risk in older adults
An, B., Ali, S., Smith, K., Roemhild, S., Neumann, L., Stoll, D. R., Li, L., Lutsey, P. L., Mielke, M. M., Fang, Y., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71893
BindingDB (2009) · UC San Diego · doi:10.7270/q25x282f
Metadata
- Authors
- Hirano, K.-I., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., & Matsuzawa, Y.
- Affiliations
- The University of Osaka (JP)
- From the Second Department of Internal Medicine, Osaka University Medical School (K-i.H., S.Y., T.A., T.M., Y.Y., M.I., N.S., K.K.-T., Y.M.), and the Nakajima Clinic, Akita (N.N.), Japan.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1997-06
- Volume
- 17
- Issue
- 6
- Pages
- 1053-1059
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2151720705
- Cited by
- 275
- References
- 40
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 9 · 2015: 11 · 2014: 9 · 2013: 11 · 2012: 15
- FWCI
- 14.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- hyperalphalipoproteinemia, HDL cholesterol, coronary artery disease, atherogenicity, genetic prevalence
- MeSH terms
- Aged, Carrier Proteins, Female, Glycoproteins, Humans, Japan, Lipid Metabolism, Inborn Errors, Lipoproteins, HDL, Longevity, Male, Middle Aged, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review